Intravitreal Dexamethasone Implant at the Time of Silicon Oil Removal to Treat Persistent Macular Edema after Rhegmatogenous Retinal Detachment Repair.
intravitreal dexamethasone implant
macular edema
rhegmatogenous retinal detachment
vitrectomy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Feb 2023
20 Feb 2023
Historique:
received:
03
01
2023
revised:
16
02
2023
accepted:
19
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
An intravitreal dexamethasone implant (DEX-I) was found to be effective and safe for the treatment of cystoid macular edema (CME) after vitrectomy for rhegmatogenous retinal detachment (RRD) and in silicone oil (SO)-filled eyes. We aimed to investigate the efficacy and safety of DEX-I at the time of SO removal for the treatment of recalcitrant CME after successful RRD repair. A retrospective review of the medical records was performed on 24 consecutive patients (24 eyes) with recalcitrant CME after RRD repair who were treated with a single 0.7-mg DEX-I at the time of SO removal. The main outcome measures were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). A regression model was performed to assess the relationship between BCVA and CMT at 6 months and independent variables. In all 24 patients, CME occurred after RRD repair and remained despite topical therapy. The mean time of CME onset was 27.4 ± 7.7 days after vitrectomy. The mean time between vitrectomy and DEX-I was 106.8 ± 10.1 days. The mean CMT was significantly decreased from 429.6 ± 59.1 µm at baseline to 294 ± 46.4 µm at month 6 ( DEX-I at the time of SO removal had an acceptable safety profile and achieved favorable outcomes in eyes affected by recalcitrant CME that occurred after RRD repair. RRD-related macular status is significantly associated with visual acuity after DEX-I.
Sections du résumé
BACKGROUND
BACKGROUND
An intravitreal dexamethasone implant (DEX-I) was found to be effective and safe for the treatment of cystoid macular edema (CME) after vitrectomy for rhegmatogenous retinal detachment (RRD) and in silicone oil (SO)-filled eyes. We aimed to investigate the efficacy and safety of DEX-I at the time of SO removal for the treatment of recalcitrant CME after successful RRD repair.
METHODS
METHODS
A retrospective review of the medical records was performed on 24 consecutive patients (24 eyes) with recalcitrant CME after RRD repair who were treated with a single 0.7-mg DEX-I at the time of SO removal. The main outcome measures were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). A regression model was performed to assess the relationship between BCVA and CMT at 6 months and independent variables.
RESULTS
RESULTS
In all 24 patients, CME occurred after RRD repair and remained despite topical therapy. The mean time of CME onset was 27.4 ± 7.7 days after vitrectomy. The mean time between vitrectomy and DEX-I was 106.8 ± 10.1 days. The mean CMT was significantly decreased from 429.6 ± 59.1 µm at baseline to 294 ± 46.4 µm at month 6 (
CONCLUSIONS
CONCLUSIONS
DEX-I at the time of SO removal had an acceptable safety profile and achieved favorable outcomes in eyes affected by recalcitrant CME that occurred after RRD repair. RRD-related macular status is significantly associated with visual acuity after DEX-I.
Identifiants
pubmed: 36836233
pii: jcm12041697
doi: 10.3390/jcm12041697
pmc: PMC9962319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mediators Inflamm. 2013;2013:971758
pubmed: 24288446
Prog Retin Eye Res. 2018 Mar;63:20-68
pubmed: 29126927
Retina. 2015 Jun;35(6):1216-22
pubmed: 25574787
Indian J Ophthalmol. 2018 Jun;66(6):831-836
pubmed: 29785994
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD004239
pubmed: 22336801
Cutan Ocul Toxicol. 2020 Mar;39(1):25-30
pubmed: 31691630
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2521-2531
pubmed: 33675394
Acta Ophthalmol. 2019 Feb;97(1):e97-e102
pubmed: 29862656
Am J Ophthalmol. 2007 Dec;144(6):872-877
pubmed: 17937924
Retina. 2012 Oct;32(9):1874-83
pubmed: 22466462
J Pharmacol Sci. 2018 Dec;138(4):219-232
pubmed: 30503676
Eye (Lond). 2015 Jul;29(7):943-50
pubmed: 25998942
Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4605-9
pubmed: 21421864
Biomed Res Int. 2014;2014:502143
pubmed: 25013785
Sci Rep. 2017 May 25;7(1):2640
pubmed: 28572674
Am J Ophthalmol. 1995 Sep;120(3):302-7
pubmed: 7661201
J Ophthalmol. 2017;2017:4896036
pubmed: 28884024
Korean J Ophthalmol. 2018 Jun;32(3):204-210
pubmed: 29022299
Curr Eye Res. 2021 Dec;46(12):1867-1875
pubmed: 33979556
Retina. 2019 Oct;39 Suppl 1:S123-S124
pubmed: 28991865
Retina. 2012 Feb;32(2):250-5
pubmed: 21926942
Int J Ophthalmol. 2014 Dec 18;7(6):1005-9
pubmed: 25540755
Ocul Immunol Inflamm. 2021 Sep 03;:1-7
pubmed: 34477484
Dev Ophthalmol. 2017;58:178-190
pubmed: 28351047
Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):31-8
pubmed: 15720233
Ocul Immunol Inflamm. 2021 Jan 2;29(1):187-192
pubmed: 31577459
Acta Ophthalmol. 2013 Aug;91(5):e340-7
pubmed: 23638803
Ophthalmology. 2014 Oct;121(10):1904-14
pubmed: 24907062
Ophthalmology. 2000 Nov;107(11):2034-8;discussion 2039
pubmed: 11054327
J Clin Med. 2022 Sep 05;11(17):
pubmed: 36079165
Front Pharmacol. 2021 Apr 15;12:635101
pubmed: 33935724
J Ophthalmol. 2020 Apr 28;2020:3946531
pubmed: 32411428
Ophthalmology. 2009 Aug;116(8):1531-7
pubmed: 19501405
J Ophthalmol. 2021 Apr 16;2021:6627677
pubmed: 33953965
Invest Ophthalmol Vis Sci. 1991 Nov;32(12):3007-20
pubmed: 1938278
Retina. 2019 Nov;39(11):2107-2115
pubmed: 30161094
Biomed Res Int. 2014;2014:372045
pubmed: 24963480
Int J Retina Vitreous. 2021 Jan 25;7(1):9
pubmed: 33494835
Arch Ophthalmol. 2000 Aug;118(8):1133-4
pubmed: 10922215
Graefes Arch Clin Exp Ophthalmol. 2004 Oct;242(10):845-52
pubmed: 15221309
Ophthalmologica. 2017;237(4):232-237
pubmed: 28463851
Medicine (Baltimore). 2021 Mar 19;100(11):e25161
pubmed: 33726001
Retina. 2018 Jun;38(6):1084-1090
pubmed: 28622270